Cargando…

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

BACKGROUND: Predicting treatment benefit and/or outcome before any therapeutic intervention has taken place would be clinically very useful. Herein, we evaluate the ability of the intrinsic subtypes and the risk of relapse score at diagnosis to predict survival and response following neoadjuvant che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prat, Aleix, Fan, Cheng, Fernández, Aranzazu, Hoadley, Katherine A., Martinello, Rossella, Vidal, Maria, Viladot, Margarita, Pineda, Estela, Arance, Ana, Muñoz, Montserrat, Paré, Laia, Cheang, Maggie C. U., Adamo, Barbara, Perou, Charles M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683815/ https://www.ncbi.nlm.nih.gov/pubmed/26684470 http://dx.doi.org/10.1186/s12916-015-0540-z

Ejemplares similares

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis
por: Aya, Francisco, et al.
Publicado: (2016)

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
por: Prat, Aleix, et al.
Publicado: (2014)

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer
por: Fernand ez-Martinez, Aranzazu, et al.
Publicado: (2017)

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
por: Prat, Aleix, et al.
Publicado: (2013)

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
por: Prat, Aleix, et al.
Publicado: (2021)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
por: Schettini, F., et al.
Publicado: (2023)

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
por: Pascual, Tomás, et al.
Publicado: (2019)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

Deconstructing the molecular portraits of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells
por: Bower, Jacquelyn J., et al.
Publicado: (2017)

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
por: Fernandez-Martinez, Aranzazu, et al.
Publicado: (2023)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy
por: Goto, Wataru, et al.
Publicado: (2018)

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
por: Lips, E. H., et al.
Publicado: (2013)

Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype
por: Couture, Heather D., et al.
Publicado: (2018)

Identification of drug targets for the treatment of Basal-like tumors
por: Hoadley, KA, et al.
Publicado: (2005)

PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
por: Prat, A., et al.
Publicado: (2012)

Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects
por: Kawashima, Hiroko, et al.
Publicado: (2014)

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
por: Gavilá, Joaquín, et al.
Publicado: (2019)

Gene expression profiles of breast cancer metastasis according to organ site
por: Brasó‐Maristany, Fara, et al.
Publicado: (2021)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

Tailored therapies based upon tumor subtype biology
por: Perou, CM
Publicado: (2005)

Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
por: Desai, Neelam V., et al.
Publicado: (2018)

EGFR associated expression profiles vary with breast tumor subtype
por: Hoadley, Katherine A, et al.
Publicado: (2007)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Intrinsic subtypes and bladder cancer metastasis
por: McConkey, David J., et al.
Publicado: (2016)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set
por: Li, Hui, et al.
Publicado: (2016)

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
por: Fan, Cheng, et al.
Publicado: (2011)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Molecular classification of triple-negative tumors
por: Prat, A, et al.
Publicado: (2011)

Identification of mRNA isoform switching in breast cancer
por: Zhao, Wei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1ebv8r0noog5poruc92600ell2